Aspire-Lakewood (ASBP) vs Biofrontera (BFRI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Aspire-Lakewood (ASBP) has outperformed Biofrontera (BFRI) over the past year, gaining 83.8% versus a loss of 28.4%. Aspire-Lakewood is the larger company by market cap ($10.0 million vs $9.5 million), about 1.1 times the size. Biofrontera converts more of its revenue into profit, with a net margin of -25.3% versus -394725.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASBP | BFRI |
|---|---|---|
| Share price | $7.13 | $0.53 |
| Market cap | $10.00M | $9.51M |
| 1-day change | -5.44% | -7.02% |
| YTD return | +35.04% | -7.02% |
| 1-year return | +83.76% | -28.38% |
| 5-year return | — | -99.66% |
| Forward P/E | — | 1.32 |
| EPS (TTM) | $-30.89 | $-0.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $6.20K | $41.70M |
| Revenue growth (YoY) | — | +11.75% |
| Net income (latest FY) | $-24.48M | $-10.54M |
| Gross margin | -1.87% | — |
| Operating margin | -312016.95% | -27.21% |
| Net margin | -394725.06% | -25.26% |
| 52-week high | $9.50 | $1.66 |
| 52-week low | $0.11 | $0.53 |
| Distance from 52-week high | -24.95% | -68.07% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +1032.08% |
| Average volume | 29.24K | 429.04K |
| Shares outstanding | 1.40M | 17.95M |
| Employees | — | 84 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ASBP has outperformed BFRI by 112.1 percentage points over the past year.
- Biofrontera is more profitable, keeping -25.3 cents of every revenue dollar as net income versus -394725.1 cents for Aspire-Lakewood.
About Aspire-Lakewood
ASBP stock →Aspire-Lakewood Holdings, Inc. develops sublingual drug delivery technology and manufactures automotive and industrial control systems.
Health Care · Biotechnology: Pharmaceutical Preparations
About Biofrontera
BFRI stock →Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions.
Health Care · Biotechnology: Pharmaceutical Preparations · 84 employees
ASBP vs BFRI FAQ
Which is bigger, Aspire-Lakewood or Biofrontera?
Aspire-Lakewood (ASBP) is larger, with a market capitalization of $10.00M compared with $9.51M for Biofrontera (BFRI).
Which stock has performed better over the past year, ASBP or BFRI?
ASBP returned +83.76% over the past 12 months, compared with -28.38% for BFRI (price return, excluding dividends). Past performance does not predict future results.
Are Aspire-Lakewood and Biofrontera in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.